The Impact of COVID-19 on Diabetic Retinopathy Monitoring and Treatment
Purpose of Review Diabetic retinopathy (DR) is one of the leading causes of vision loss worldwide. Although screening and early treatment guidelines for DR have significantly reduced the disease burden, restrictions related to the COVID-19 pandemic have changed real-world practice patterns in the ma...
Gespeichert in:
| Veröffentlicht in: | Current diabetes reports 2021-10, Vol.21 (10), p.40-40, Article 40 |
|---|---|
| Hauptverfasser: | , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 40 |
|---|---|
| container_issue | 10 |
| container_start_page | 40 |
| container_title | Current diabetes reports |
| container_volume | 21 |
| creator | Ahmed, Ishrat Liu, T. Y. Alvin |
| description | Purpose of Review
Diabetic retinopathy (DR) is one of the leading causes of vision loss worldwide. Although screening and early treatment guidelines for DR have significantly reduced the disease burden, restrictions related to the COVID-19 pandemic have changed real-world practice patterns in the management of DR. This review summarizes evolving guidelines and outcomes of the treatment of DR in the setting of the pandemic.
Recent Findings
Intravitreal injections for DR have decreased significantly globally during the pandemic, ranging from approximately 30 to nearly 100% reduction, compared to corresponding timepoints in 2019. Most studies on functional outcomes show a decrease in visual acuity on delayed follow-up.
Summary
Changing practice patterns in the management of DR has led to fewer intravitreal injections and overall reduction in visual acuity on follow-up. As COVID variants emerge, it will be necessary to continue evaluating practice guidelines. |
| doi_str_mv | 10.1007/s11892-021-01411-6 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8425316</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2570371325</sourcerecordid><originalsourceid>FETCH-LOGICAL-c474t-f0f2e3ab7f3cf497446dd9698e03bd3055b131ef9c62b54177ef6b88ebd2ee6f3</originalsourceid><addsrcrecordid>eNp9kctq3DAUhkVoSdJJXyCLIOgmG7W6WtamUCZtOpASCNNuhWwfZRzGkit5Ann7aOI0vSy60RGc7_zn8iN0yuh7Rqn-kBmrDSeUM0KZZIxUB-iYKWEIrbl59fSXRNZcH6E3Od9RykuZOkRHQkqjhNbH6HK9AbwaRtdOOHq8vP6xuiDM4BjwRe8amPoW35Q3xNFNmwf8LYZ-iqkPt9iFDq8TuGmAMJ2g195tM7x9jgv0_cvn9fIrubq-XC0_XZFWajkRTz0H4RrtReul0VJWXWcqUwMVTSeoUg0TDLxpK94oybQGXzV1DU3HASovFujjrDvumgG6trRObmvH1A8uPdjoevt3JvQbexvvbS25EqwqAufPAin-3EGe7NDnFrZbFyDusuVKU6GZKPQCvfsHvYu7FMp6M8UUp6JQfKbaFHNO4F-GYdTufbKzT7b4ZJ98svspzv5c46XklzEFEDOQx_2xIf3u_R_ZR67lnRs</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2570315203</pqid></control><display><type>article</type><title>The Impact of COVID-19 on Diabetic Retinopathy Monitoring and Treatment</title><source>MEDLINE</source><source>SpringerLink Journals</source><creator>Ahmed, Ishrat ; Liu, T. Y. Alvin</creator><creatorcontrib>Ahmed, Ishrat ; Liu, T. Y. Alvin</creatorcontrib><description>Purpose of Review
Diabetic retinopathy (DR) is one of the leading causes of vision loss worldwide. Although screening and early treatment guidelines for DR have significantly reduced the disease burden, restrictions related to the COVID-19 pandemic have changed real-world practice patterns in the management of DR. This review summarizes evolving guidelines and outcomes of the treatment of DR in the setting of the pandemic.
Recent Findings
Intravitreal injections for DR have decreased significantly globally during the pandemic, ranging from approximately 30 to nearly 100% reduction, compared to corresponding timepoints in 2019. Most studies on functional outcomes show a decrease in visual acuity on delayed follow-up.
Summary
Changing practice patterns in the management of DR has led to fewer intravitreal injections and overall reduction in visual acuity on follow-up. As COVID variants emerge, it will be necessary to continue evaluating practice guidelines.</description><identifier>ISSN: 1534-4827</identifier><identifier>EISSN: 1539-0829</identifier><identifier>DOI: 10.1007/s11892-021-01411-6</identifier><identifier>PMID: 34495377</identifier><language>eng</language><publisher>New York: Springer US</publisher><subject>Coronaviruses ; COVID-19 ; Diabetes ; Diabetic retinopathy ; Diabetic Retinopathy - diagnosis ; Diabetic Retinopathy - drug therapy ; Follow-Up Studies ; Humans ; Medicine ; Medicine & Public Health ; Microvascular Complications—Retinopathy (R Channa ; Microvascular Complications—Retinopathy (R Channa, Section Editor) ; Pandemics ; SARS-CoV-2 ; Section Editor ; Topical Collection on Microvascular Complications—Retinopathy ; Treatment Outcome</subject><ispartof>Current diabetes reports, 2021-10, Vol.21 (10), p.40-40, Article 40</ispartof><rights>The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature 2021</rights><rights>2021. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.</rights><rights>The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature 2021.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c474t-f0f2e3ab7f3cf497446dd9698e03bd3055b131ef9c62b54177ef6b88ebd2ee6f3</citedby><cites>FETCH-LOGICAL-c474t-f0f2e3ab7f3cf497446dd9698e03bd3055b131ef9c62b54177ef6b88ebd2ee6f3</cites><orcidid>0000-0003-2957-0755</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s11892-021-01411-6$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s11892-021-01411-6$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>230,314,780,784,885,27924,27925,41488,42557,51319</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/34495377$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Ahmed, Ishrat</creatorcontrib><creatorcontrib>Liu, T. Y. Alvin</creatorcontrib><title>The Impact of COVID-19 on Diabetic Retinopathy Monitoring and Treatment</title><title>Current diabetes reports</title><addtitle>Curr Diab Rep</addtitle><addtitle>Curr Diab Rep</addtitle><description>Purpose of Review
Diabetic retinopathy (DR) is one of the leading causes of vision loss worldwide. Although screening and early treatment guidelines for DR have significantly reduced the disease burden, restrictions related to the COVID-19 pandemic have changed real-world practice patterns in the management of DR. This review summarizes evolving guidelines and outcomes of the treatment of DR in the setting of the pandemic.
Recent Findings
Intravitreal injections for DR have decreased significantly globally during the pandemic, ranging from approximately 30 to nearly 100% reduction, compared to corresponding timepoints in 2019. Most studies on functional outcomes show a decrease in visual acuity on delayed follow-up.
Summary
Changing practice patterns in the management of DR has led to fewer intravitreal injections and overall reduction in visual acuity on follow-up. As COVID variants emerge, it will be necessary to continue evaluating practice guidelines.</description><subject>Coronaviruses</subject><subject>COVID-19</subject><subject>Diabetes</subject><subject>Diabetic retinopathy</subject><subject>Diabetic Retinopathy - diagnosis</subject><subject>Diabetic Retinopathy - drug therapy</subject><subject>Follow-Up Studies</subject><subject>Humans</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Microvascular Complications—Retinopathy (R Channa</subject><subject>Microvascular Complications—Retinopathy (R Channa, Section Editor)</subject><subject>Pandemics</subject><subject>SARS-CoV-2</subject><subject>Section Editor</subject><subject>Topical Collection on Microvascular Complications—Retinopathy</subject><subject>Treatment Outcome</subject><issn>1534-4827</issn><issn>1539-0829</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><recordid>eNp9kctq3DAUhkVoSdJJXyCLIOgmG7W6WtamUCZtOpASCNNuhWwfZRzGkit5Ann7aOI0vSy60RGc7_zn8iN0yuh7Rqn-kBmrDSeUM0KZZIxUB-iYKWEIrbl59fSXRNZcH6E3Od9RykuZOkRHQkqjhNbH6HK9AbwaRtdOOHq8vP6xuiDM4BjwRe8amPoW35Q3xNFNmwf8LYZ-iqkPt9iFDq8TuGmAMJ2g195tM7x9jgv0_cvn9fIrubq-XC0_XZFWajkRTz0H4RrtReul0VJWXWcqUwMVTSeoUg0TDLxpK94oybQGXzV1DU3HASovFujjrDvumgG6trRObmvH1A8uPdjoevt3JvQbexvvbS25EqwqAufPAin-3EGe7NDnFrZbFyDusuVKU6GZKPQCvfsHvYu7FMp6M8UUp6JQfKbaFHNO4F-GYdTufbKzT7b4ZJ98svspzv5c46XklzEFEDOQx_2xIf3u_R_ZR67lnRs</recordid><startdate>20211001</startdate><enddate>20211001</enddate><creator>Ahmed, Ishrat</creator><creator>Liu, T. Y. Alvin</creator><general>Springer US</general><general>Springer Nature B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7RV</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>KB0</scope><scope>M0S</scope><scope>M1P</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0003-2957-0755</orcidid></search><sort><creationdate>20211001</creationdate><title>The Impact of COVID-19 on Diabetic Retinopathy Monitoring and Treatment</title><author>Ahmed, Ishrat ; Liu, T. Y. Alvin</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c474t-f0f2e3ab7f3cf497446dd9698e03bd3055b131ef9c62b54177ef6b88ebd2ee6f3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Coronaviruses</topic><topic>COVID-19</topic><topic>Diabetes</topic><topic>Diabetic retinopathy</topic><topic>Diabetic Retinopathy - diagnosis</topic><topic>Diabetic Retinopathy - drug therapy</topic><topic>Follow-Up Studies</topic><topic>Humans</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Microvascular Complications—Retinopathy (R Channa</topic><topic>Microvascular Complications—Retinopathy (R Channa, Section Editor)</topic><topic>Pandemics</topic><topic>SARS-CoV-2</topic><topic>Section Editor</topic><topic>Topical Collection on Microvascular Complications—Retinopathy</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Ahmed, Ishrat</creatorcontrib><creatorcontrib>Liu, T. Y. Alvin</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Nursing & Allied Health Database</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Current diabetes reports</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Ahmed, Ishrat</au><au>Liu, T. Y. Alvin</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>The Impact of COVID-19 on Diabetic Retinopathy Monitoring and Treatment</atitle><jtitle>Current diabetes reports</jtitle><stitle>Curr Diab Rep</stitle><addtitle>Curr Diab Rep</addtitle><date>2021-10-01</date><risdate>2021</risdate><volume>21</volume><issue>10</issue><spage>40</spage><epage>40</epage><pages>40-40</pages><artnum>40</artnum><issn>1534-4827</issn><eissn>1539-0829</eissn><abstract>Purpose of Review
Diabetic retinopathy (DR) is one of the leading causes of vision loss worldwide. Although screening and early treatment guidelines for DR have significantly reduced the disease burden, restrictions related to the COVID-19 pandemic have changed real-world practice patterns in the management of DR. This review summarizes evolving guidelines and outcomes of the treatment of DR in the setting of the pandemic.
Recent Findings
Intravitreal injections for DR have decreased significantly globally during the pandemic, ranging from approximately 30 to nearly 100% reduction, compared to corresponding timepoints in 2019. Most studies on functional outcomes show a decrease in visual acuity on delayed follow-up.
Summary
Changing practice patterns in the management of DR has led to fewer intravitreal injections and overall reduction in visual acuity on follow-up. As COVID variants emerge, it will be necessary to continue evaluating practice guidelines.</abstract><cop>New York</cop><pub>Springer US</pub><pmid>34495377</pmid><doi>10.1007/s11892-021-01411-6</doi><tpages>1</tpages><orcidid>https://orcid.org/0000-0003-2957-0755</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1534-4827 |
| ispartof | Current diabetes reports, 2021-10, Vol.21 (10), p.40-40, Article 40 |
| issn | 1534-4827 1539-0829 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8425316 |
| source | MEDLINE; SpringerLink Journals |
| subjects | Coronaviruses COVID-19 Diabetes Diabetic retinopathy Diabetic Retinopathy - diagnosis Diabetic Retinopathy - drug therapy Follow-Up Studies Humans Medicine Medicine & Public Health Microvascular Complications—Retinopathy (R Channa Microvascular Complications—Retinopathy (R Channa, Section Editor) Pandemics SARS-CoV-2 Section Editor Topical Collection on Microvascular Complications—Retinopathy Treatment Outcome |
| title | The Impact of COVID-19 on Diabetic Retinopathy Monitoring and Treatment |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-26T00%3A04%3A22IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=The%20Impact%20of%20COVID-19%20on%20Diabetic%20Retinopathy%20Monitoring%20and%20Treatment&rft.jtitle=Current%20diabetes%20reports&rft.au=Ahmed,%20Ishrat&rft.date=2021-10-01&rft.volume=21&rft.issue=10&rft.spage=40&rft.epage=40&rft.pages=40-40&rft.artnum=40&rft.issn=1534-4827&rft.eissn=1539-0829&rft_id=info:doi/10.1007/s11892-021-01411-6&rft_dat=%3Cproquest_pubme%3E2570371325%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2570315203&rft_id=info:pmid/34495377&rfr_iscdi=true |